There are different ways to measure how Medicare Shared Savings Program (MSSP) accountable care organizations (ACOs) have saved money, and the way used can drastically affect the amount of savings reported, explained Clif Gaus, ScD, president and CEO of the National Association of ACOs.
There are different ways to measure how Medicare Shared Savings Program (MSSP) accountable care organizations (ACOs) have saved money, and the way used can drastically affect the amount of savings reported, explained Clif Gaus, ScD, president and CEO of the National Association of ACOs.
Transcript
NAACOS recently released a study about how much MSSP ACOs are savings, and the findings differ greatly from what CMS has reported but are in line with research out of Harvard. What are the savings NAACOS found and what is the controversy around how to measure savings?
So, there are really are 2 ways of measuring costs and performance. The first way is the MSSP benchmark way. The benchmarks are set based on historical costs, and over a 3-year period, and then trended forward for the performance year. However, those benchmarks are capped in terms of when risk changes and goes up, the benchmark doesn’t go up. So, the patients may become sicker in the subsequent years, and cost more, but the benchmark doesn’t increase. So, ACOs are against a much harder goal or bar of performance, and therefore not always achieving as much savings as much as they truly are.
The other way of measuring is to compare precisely the ACO beneficiaries based on their risk, based on their geography, their age, and match those beneficiaries to a control group of beneficiaries who are not in the ACO, but who are living in the same geographic area, have the same illnesses, etc. And when you compare those 2 groups—the ACO beneficiaries and the like nonbeneficiaries—over time, what you see is that the ACO beneficiaries’ costs are substantially lower than the control group by almost 2-fold.
So, CMS based on benchmarks was showing gross savings of, I think it was in the range of $900 million from 2013, 2014, 2015. But when you compare them to the savings from the control group, those savings were $1.8 billion. So, the savings essentially based upon that match control group are twice what CMS was estimating.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: UnitedHealth Lawsuit; Fentanyl Crackdown; Global Heat Deaths Increase
November 15th 2023A class action lawsuit was filed against UnitedHealth Group and a subsidiary for allegedly using an algorithm to deny rehabilitation coverage for seriously ill patients; US and China officials are finalizing an agreement to crack down on fentanyl; a study published Tuesday projected global heat deaths to increase by 370% if no action is taken against global warming.
Read More